October 8, 2026

VIA EDGAR AND E-MAIL

Jessica Dickerson
Office of Life Sciences
Division of Corporate Finance
U.S. Securities and Exchange Commission
100 F. Street, N.E.
Washington, DC 20549-7010

Re: HCW Biologics Inc. Registration Statement on Form S-1;
Commission File No. 333-299271

Dear Mr. Campbell:

Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, HCW Biologics Inc. (the "Company") hereby requests that the effectiveness of the above referenced Registration Statement on Form S-1 be accelerated by the U.S. Securities and Exchange Commission to 3:00 p.m. Eastern Time on Friday, October 9, 2026, or as soon thereafter as is practicable.

The Company hereby authorizes James Groth or Jeny Zarmon of Clark Hill PLC to orally modify or withdraw this request for acceleration. Please contact Mr. Groth at (312) 701-6830 or Ms. Zarmon at (609) 785-2918 with any questions you may have concerning this request, and please notify them when this request for acceleration has been granted.

Thank you for your courtesy and cooperation in this matter.

Very truly yours,

HCW BIOLOGICS INC.

By: */s/ Hing Wong*
Hing Wong, Founder and CEO

HCW Biologics acceleration request for S-1 October 2026